Inflammatory bowel disease (IBD) is a common and debilitating clinical disorder comprising ulcerative colitis and Crohn's disease. IBD occurs when inappropriate immunological activity in the intestinal mucosa results in epithelial barrier dysfunction leading to exposure of the mucosal immune system to luminal antigenic material. This in turn results in the cycles of inflammation and further barrier dysfunction which underlie disease progression. Although significant therapeutic advances have been made over the last decade, current immunosuppressive and anti-inflammatory treatments for IBD have significant limitations due to lack of treatment response in some patients and adverse effects, including increased risk of infection and malignancy. Recent studies using experimental models of IBD have identified that intracellular hydroxylases, a group of enzymes responsible for oxygen sensing and activation of adaptive transcriptional responses to hypoxia may represent a new class of therapeutic targets in IBD. Hydroxylase inhibitors are effective in ameliorating symptoms of colitis at least in part through the promotion of intestinal epithelial barrier function. The mechanism of this protection is due to activation of hypoxia-sensitive transcription factors, including the hypoxiainducible factor (HIF) and nuclear factor kappa-B (NF-kB), which activate specific epithelial barrier-protective transcriptional programs. In this review, the mechanism(s) of action and the therapeutic potential of small molecule hydroxylase inhibitors for the treatment of IBD will be discussed.
Inflammatory Bowel Disease (IBD)
IBD is an umbrella term used to describe a heterogeneous family of conditions, including ulcerative colitis and Crohn's disease. Ulcerative colitis, which is restricted to the colonic mucosa was first described in the mid 19th century and it's worldwide prevalence has been steadily increasing since the middle of the 20th century. 1,2 Crohn's disease, first described in 1932, is often transmural and can affect any portion of the gastro-intestinal tract with inflammation seen most commonly in the ileum and/or colon. 3, 4 Peak incidence of IBD occurs in early adulthood and it's prevalence results in high individual and societal costs. 5 Current incidence and prevalence rates of IBD are 8-14 per 100 000 persons and 120-200 per 100 000 persons, respectively. 6 Furthermore, there has been a recently described increase in the incidence of IBD in developed countries. 7 Experimental, genetic and clinical evidence indicates that IBD 'results from an inappropriate inflammatory response to intestinal microbes in a genetically susceptible host' . 4 However, this susceptibility has been associated with mutations at multiple chromosomal loci making the relationship between genetics and IBD-susceptibility complex. 4, [8] [9] [10] To date, the greatest documented risk of IBD susceptibility occurs in individuals with a homozygous polymorphism in the NOD2 gene, which encodes a bacterial peptidoglycan receptor associated with activity of the nuclear factor kappa-B (NF-kB) transcriptional pathway. 11 Other genes reported to affect susceptibility to IBD, include CARD9, IL23R and MUC19 which encode proteins associated with innate immune signaling, cytokine signaling and mucin production, respectively. 10, [12] [13] [14] CARD9 is involved in the regulation of hypoxia-sensitive pathways. 15 While the underlying cause of IBD is complex and multifactorial involving the epithelial barrier, innate immune defenses and the intestinal microbiome, ultimately, it is a loss of intestinal epithelial barrier function with subsequent uncontrolled exposure of the mucosal immune system to the luminal microbiome with resultant amplification of mucosal inflammation, which allows the disease to progress. 4 The symptoms of IBD can range from mild to severe and include abdominal pain, intestinal bleeding, weight loss, fever and diarrhea. 16 The therapeutic approach to IBD typically involves multidisciplinary management, including medical management which employs the use of broad spectrum immunosuppressants to reduce mucosal inflammation. 16 Traditionally, a step-up approach to the therapy of IBD has been used, which involves the use of 5-aminosalicylate-based compounds (eg mesalazine) as a first line approach followed by corticosteroids (eg prednisolone). Immunomodulators such as azathioprine, 6-mercaptopurine and methotrexate have been increasingly used as maintenance treatment (typically as a corticosteroid sparing strategy). The treatment of IBD has more recently been revolutionized by the development of targeted molecular agents with the use of therapeutic antibodies against TNFalpha (anti-TNF) to suppress mucosal inflammation. 17, 18 The step-up approach for the treatment of IBD has been challenged with the emergence of such 'biologic' agents and a 'top-down' therapeutic paradigm has been proposed, which advocates early aggressive use of therapeutic antibodies as a first line of treatment. 19 However, early use of therapeutic antibodies, typically combined with immunomodulators to promote mucosal healing may also lead to increased risk of toxicity, infections and the rare risk of hepatosplenic T-cell lymphoma in young men. [20] [21] [22] While current therapeutic approaches reduce disease activity and improve symptoms, the degree to which sustained mucosal healing has been achieved has been disappointing in randomized-controlled trials in both ulcerative colitis and Crohn's disease. 23 A number of key limitations still exist with current therapeutic options. These include nonresponsiveness of patients to 5-ASA, side-effects associated with high-level and prolonged corticosteroid usage and nonresponse/loss of response, high cost and increased risk of infection and malignancy with the use of biologic agents, especially when combined with immunomodulators. 17, 24 Indeed, despite therapeutic developments, the numbers of patients ultimately requiring surgical intervention remains high. 25 With this in mind, there is a significant need for new approaches to the treatment of IBD, which may be used in addition to or in combination with existing approaches to alleviate symptoms in patients.
Tissue Hypoxia in IBD Physiologic perfusion of the gastro-intestinal tract fluctuates according to whether or not food has been recently consumed and increased tissue perfusion is required to facilitate the necessary oxygen delivery and nutrient absorption. 26 In the normal state, the epithelium of the richly perfused mucosal bed of the intestine is in direct contact with the anoxic lumen of the gut which houses the intestinal microbiome. As a result of this juxtaposition, there normally exists a uniquely steep trans-mucosal oxygen gradient ranging from relatively high levels of oxygen in vascular bed to the anoxic conditions at the luminal-epithelial interface. [26] [27] [28] Whether oxygen consumption by the intestinal microbiome contributes to this steep physiologic oxygen gradient currently remains unknown, however, there is evidence for bacteriaassociated oxygen consumption and activation of hypoxiasensitive pathways in the context of pathogen infection. 29 When inflamed, the microenvironment of the intestinal mucosa demonstrates a high degree of hypoxia, likely reflective of vascular disruption due to chronic inflammation in combination with increased oxygen demand by highly metabolically active infiltrating immune and inflamed resident cells. 28, 30 Furthermore, it is likely that the high oxygen requirements of infiltrating neutrophils, used to generate reactive oxygen species in the oxidative burst, likely contributes to a large increase in oxygen consumption. The existence of mucosal hypoxia during chronic inflammation is supported by studies demonstrating elevated levels of hypoxia-dependent proteins such as hypoxia-inducible factor (HIF) (see below) in biopsies taken from regions of active IBD. 31 Therefore, significant evidence now supports the existence of prominent areas of focal hypoxia in inflamed regions of the colon in active IBD. Interestingly, the coexistence of hypoxia and inflammation is not restricted to IBD as other chronically inflamed tissues such as arthritic joints also demonstrate tissue hypoxia. 32, 33 Hypoxia-Sensitive Transcriptional Pathways Hypoxia arises when the cellular demand for oxygen exceeds the vascular supply and is associated with a wide range of physiologic and pathophysiologic conditions where either oxygen delivery is decreased (eg fetal development, ischemia, cancer) or where oxygen demand is increased (eg exercise, inflammation). Because the energy provided by the chemical reduction of molecular oxygen by the mitochondrial electron transport chain is the primary source of metabolic energy used to fuel all biochemical reactions, it is perhaps not surprising that eukaryotes have evolved the capacity to deal with hypoxia at the transcriptional level with the induction of a range of hypoxia-sensitive genes. 34, 35 Primary among the hypoxia responsive transcriptional regulators is the HIF a dimeric transcription factor, the abundance of which is regulated by oxygen availability across the physiologic range in cells, and which controls the expression of over 300 genes responsible for regaining oxygen homeostasis in hypoxic tissues. HIF-dependent genes include factors affecting angiogenesis, metabolism, vascular tone and cell survival. As well as having a central role in the adaptive response to hypoxia, HIF has more recently been appreciated as a key regulator of innate immunity and inflammation. 28, 36, 37 Indeed, conditional knockout of the HIF-1a isoform has revealed a key role for HIF in mediating functional immune responses in macrophages, dendritic cells, T-cells and neutrophils. [38] [39] [40] [41] [42] The expression of hypoxia-inducible transcription factors such as HIF in mucosal tissue has been demonstrated to be increased in diseases of the GI tract including celiac disease 43 and IBD. 31 Although most studies support a protective role for HIF activation in inflammatory conditions of the gut, 27, 44, 45 its activation has also been proposed to be detrimental. 46 The cellular transcriptional response to hypoxia is not restricted to regulation by HIF and multiple other transcriptional pathways demonstrate hypoxic sensitivity. 47 Principal among the HIF-independent transcription factors, which display hypoxic sensitivity is NF-kB, a master regulator of innate immune and inflammatory gene expression. 48 ,49 NF-kB -dependent genes include cytokines, adhesion molecules and regulators of cellular apoptosis. 50, 51 Indeed, NF-kB signaling in intestinal epithelial cells has been shown to be protective against the development of colitis. 52 However, while hypoxia represents a strong and primary stimulus for HIF, it is a more moderate stimulus for NF-kB signaling, which may favor the expression of an antiapoptotic rather than proinflammatory pattern of NF-kB dependent gene expression. Thus, in response to hypoxic stress, cells are capable of switching on protective transcriptional responses, which are mediated by hypoxia-sensitive transcription factors such as HIF and NF-kB.
Hydroxylases as Intracellular Oxygen Sensors
The mechanism underpinning the hypoxic-sensitivity of HIF was discovered in 2001. 53, 54 This elegant yet surprisingly simple and highly conserved mechanism has recently been expertly reviewed. 55, 56 In brief, under conditions where mitochondrial oxygen demand is satisfied and 'spare' nonmitochondrial oxygen is available, a family of three prolyl hydroxylases (PHD1-3) and a single asparagine hydroxylase (FIH) are active and are responsible for the hydroxylationdependent targeting of the HIFa subunit for ubiquitylation by the von Hipple Lindau E3 ligase complex leading to proteasomal degradation. Under conditions of hypoxia, where oxygen availability is limiting, the HIF hydroxylases are inhibited allowing the stabilization of a transcriptionally active HIFa/b dimer and the subsequent expression of HIFdependent genes. Subsequent studies revealed that the mechanism by which hypoxia leads to activation of NF-kB is also largely dependent upon altered HIF-hydroxylase activity. [57] [58] [59] Hydroxylase Inhibitors in Models of IBD As outlined above, hydroxylases are key oxygen sensors, which confer hypoxic sensitivity to transcriptional regulators including HIF and NF-kB, both of which are protective against colitis when activated in intestinal epithelial cells. As HIF and NF-kB are key regulators of both immune and inflammatory processes 35, 37 it was initially proposed that pharmacologic hydroxylase inhibition, leading to enhanced HIF and NF-kB activity may be of therapeutic benefit in chronic inflammatory conditions such as IBD. Indeed, several studies provided evidence that pharmacologic hydroxylase inhibition with compounds such as DMOG or FG-4497 is protective in murine models of colitis. 60, 61 While these initial studies utilized chemical models of acute colitis, subsequent studies using genetic-, ischemic-and toxin-based acute and chronic models support a protective role for hydroxylase inhibition in colitis. 44, 45, 62, 63 More recently, the mechanisms underpinning the protective effects of hydroxylase inhibitors have become clearer (Figure 1) . These mechanisms will be described below.
PROTECTIVE MECHANISMS OF HYDROXYLASE INHIBITORS IN IBD Inhibition of Intestinal Epithelial Cell Apoptosis
One mechanism which may contribute to the protective effects of pharmacologic hydroxylase inhibition in colitis is through the promotion of intestinal barrier function through inhibition of epithelial cell apoptosis. Intestinal epithelial cells have a relatively short lifespan lasting 48-72 h in vivo during which they have an important role in epithelial barrier function as they migrate up the intestinal crypt and villus before undergoing apoptosis and being shed into the intestinal lumen. Consequently, the rate of intestinal epithelial cell apoptosis is central to the maintenance of an intact intestinal barrier. 64 The rate of intestinal epithelial cell apoptosis is increased in IBD leading to a loss of intestinal barrier function with subsequent exposure of the mucosal immune system to the microbiota. 65 Initial studies into the protective effects of pharmacologic hydroxylase inhibition revealed an antiapoptotic role for the pan-hydroxylase inhibitor DMOG in DSS colitis. 60 This was associated with elevated levels of the antiapoptotic protein cIAP-2 in DMOGtreated mice compared with controls when treated with DSS. Further investigations implicated the PHD1 isoform as the key hydroxylase isoform regulating intestinal epithelial cell apoptosis. 66 In this study, mice homozygous deficient for PHD1 were protected in a model of DSS-induced colitis while PHD2-deficient heterozygotes and PHD3-deficient homozygotes were equally as susceptible as wild-type controls. 66 In summary, inhibition of intestinal epithelial cell apoptosis with a resultant increase in intestinal barrier function is a key mechanism by which pharmacologic hydroxylase inhibition is protective in experimental models of colitis.
Enhanced Expression of Barrier Protective Genes
Recent work has identified a 'barrier protective' transcriptional signature in intestinal epithelial cells exposed to hypoxia or pharmacologic hydroxylase inhibition. The primary regulator of this transcriptional signature is HIF-1a.
Initially it was demonstrated that conditional knockout of HIF-1a in mouse intestinal epithelial cells results in enhanced susceptibility to the development of colitis. 27 Further studies demonstrated that among the HIF-dependent epithelial genes involved in the resolution of inflammatory events were CD55 which is involved in the clearance of neutrophils, 67 ecto-5 0 nucleotidase and the A2B receptor, which promote enhanced adenosine signaling contributing to the resolution of mucosal inflammation, 68, 69 MUC-3 and intestinal trefoil factor which lead to the formation of a protective mucous layer, 70,71 P-glycoprotein which is involved in intestinal epithelial cell homeostasis and host-bacteria interactions. 28, 30, 72 Therefore, a third mechanism whereby pharmacologic hydroxylase inhibition may provide protection in murine models of colitis is through enhancing the expression of a battery of epithelial-specific barrier protective genes via the HIF pathway.
Promotion of Neutrophil Apoptosis
A third mechanism whereby pharmacologic hydroxylase inhibition may have anti-inflammatory effects in colitis is via the regulation of neutrophil apoptosis. 73 Neutrophil infiltration and the formation of colonic crypt abscesses is a hallmark of IBD and the regulation of neutrophil lifespan is consequently a key event in determining the extent and duration of inflammation. Hypoxia-dependent pathways have been previously demonstrated to have an important role in the regulation of neutrophil apoptosis. PHD3 loss results in decreased-neutrophil survival under hypoxic conditions. 73 Furthermore, in mice which are homozygous deficient in PHD3, there is a reduction in neutrophilic inflammation in DSS-induced colitis. 73 Therefore, enhanced neutrophil apoptosis is another mechanism by which pharmacologic hydroxylase inhibition may be protective in murine models of colitis. While HIF-1a has been shown to be important in regulating the immunological function of other immune cells such as macrophages, T-cells and dendritic cells, how this contributes to the anti-inflammatory effects of hydroxylase inhibitors in IBD currently remains unknown.
Potential Risks Associated with the Use of Hydroxylase Inhibitors
Because hydroxylase inhibition leads to the activation of HIF, NF-kB and likely other transcriptional pathways, a number of possible risks may be associated with their use. Firstly, a possible unwanted side effect of systemic hydroxylase inhibitor administration is elevated Epo levels with associated erythropoiesis. While this may be desirable in the treatment of anemic patients, it may increase the risk of cardiovascular events in non-anemic patients due to overstimulation of erythropoiesis. Furthermore, because HIF regulates the expression of glycolytic enzymes and components of the mitochondrial electron transport chain, it is possible that systemic hydroxylase inhibition could impact upon metabolic processes, however the in vivo implications for this currently remain unknown. Secondly, at least theoretically, there could be increased risk of the promotion of growth of pre-existing tumors through the promotion of HIF-dependent angiogenesis. Currently, little data exists relating to the real possibility of such risks in patients. However, in the context of treating IBD, an attractive therapeutic option would be the directed delivery of hydroxylase inhibitors to inflamed regions of the intestine over short therapeutic windows using formulated preparations to enhance drug delivery to the site of inflammation and minimize systemic exposure.
SUMMARY
In summary, metazoan cells poses an evolutionarily conserved oxygen sensing pathway, which is governed by a family of oxygen dependent hydroxylases that control the activity of transcription factors such as HIF and NF-kB. A number of recently published studies support the possible use of hydroxylase inhibitors in the treatment of IBD. Furthermore, targeted administration of such agents specifically to inflamed regions of the intestine over a short therapeutic timeframe to promote epithelial restitution would reduce the risk of any potential side effects and decrease the pharmaceutical burden imposed.
